Innovative Pipeline Oblique Therapeutics AB is actively developing antibody-based therapies targeting severe diseases with unmet medical needs, especially in pain management, presenting opportunities for partners interested in novel biotech solutions.
Strategic Collaborations The company's recent partnerships with AAX Biotech, Targovax, and others highlight a collaborative approach to expanding its technological capabilities, offering potential for joint ventures and licensing deals.
Focused Technology Platform Using its proprietary Abiprot antibody platform to identify accessible epitopes positions Oblique as a potential vendor or collaborator for companies seeking innovative antibody development tools.
Therapeutic Focus Areas Development of antibodies such as TRPV1 and potential collaborations in immuno-oncology open multiple avenues for sales of specialized biologics and research tools to pharma and biotech companies.
$25M$50M
$10M$25M
$10M$25M
$1M$10M
$1M$10M
$10M$25M
$1M$10M
$1M$10M
$1M$10M
$1M$10MOblique Therapeutics AB (publ.) uses 8 technology products and services including WordPress, RSS, Twemoji, and more. Explore Oblique Therapeutics AB (publ.)'s tech stack below.
| Oblique Therapeutics AB (publ.) Email Formats | Percentage |
| First.Last@obliquet.com | 37% |
| First@obliquet.com | 13% |
| First.Last@obliquet.com | 37% |
| First@obliquet.com | 13% |
Pharmaceutical ManufacturingVästra Götaland, Sweden11-50 Employees
Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need with an internal pipeline focusing on pain. The company uses Abiprot®, a proprietary, next-generation antibody platform to identify accessible epitopes for antibody development.
Company Overview
Funding & FinancialsOblique Therapeutics AB (publ.) has raised a total of $2.5M of funding over 1 rounds. Their latest funding round was raised on Dec 11, 2015 in the amount of $2.5M.
Oblique Therapeutics AB (publ.)'s revenue is estimated to be in the range of $1M
Funding & FinancialsOblique Therapeutics AB (publ.) has raised a total of $2.5M of funding over 1 rounds. Their latest funding round was raised on Dec 11, 2015 in the amount of $2.5M.
Oblique Therapeutics AB (publ.)'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com